Some drugs in UK to skip cost-effectiveness appraisal
This article was originally published in SRA
Executive Summary
The UK government will allow for a limited period of time certain innovative medicines to be used by the National Health Service without them having been evaluated for cost effectiveness by the country’s health technology assessment body, the National Institute for Health and Clinical Excellence1.